Published in Climacteric on August 01, 2014
Efficacy of exercise for menopausal symptoms: a randomized controlled trial. Menopause (2014) 1.67
Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial. Menopause (2014) 1.44
Efficacy of yoga for vasomotor symptoms: a randomized controlled trial. Menopause (2014) 1.44
Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas (2005) 1.37
IMS updated recommendations on postmenopausal hormone therapy. Climacteric (2007) 1.20
Systemic hypertension in postmenopausal women: a clinical approach. Curr Hypertens Rep (2002) 0.81
More data on hormone therapy and coronary artery disease: comments on recent publications from the WHI and Nurses' Study. Climacteric (2006) 0.77
Re: Estrogen plus progestin and breast cancer incidence and mortality in the women's health initiative observational study. J Natl Cancer Inst (2013) 0.76
Hormone therapy and cardiovascular disease in the early postmenopause: the WHI data revisited. Climacteric (2007) 0.76
Antihypertensives and breast cancer risk. Climacteric (2013) 0.75
In anticipation of menopause. Menopause (2011) 0.75
Menopausal hormone therapy and risk for cardiovascular disease in the WHI trial. Ann Intern Med (2010) 0.75
Keep your weight--don't miss breakfast. Climacteric (2014) 0.75
Do women really take their osteoporosis therapy? Climacteric (2014) 0.75
Exercise, breast size and cancer risk. Climacteric (2014) 0.75
Primary prevention of stroke in women. Climacteric (2014) 0.75
The healing properties of exercise. Menopause (2006) 0.75
The importance of HT dose, formulation and route of delivery. Climacteric (2014) 0.75
Climacteric commentaries. Climacteric (2013) 0.75
Controlling caloric intake and energy expenditure may not be enough to keep weight stable. Climacteric (2013) 0.75
Should we be satisfied with the available anti-fracture therapies? Climacteric (2013) 0.75
Menopause issues in Nigeria. Climacteric (2014) 0.75
Use of complementary and traditional medicine in the menopause. Climacteric (2014) 0.75
Routine calcium and vitamin D supplementation: the end of the story? Climacteric (2014) 0.75
Safety of low-dose paroxetine. Climacteric (2014) 0.75
Breast cancer risk and pretreatment estrogen levels. Climacteric (2014) 0.75
Compliance with hormone therapy after Women's Health Initiative: who is to blame? Menopause (2005) 0.75
Sugary foods and gynecological cancer risk. Climacteric (2013) 0.75
Ebola in women--what the Ob-Gyns should know. Climacteric (2015) 0.75
Postmenopausal hormone therapy and blood pressure revisited. Climacteric (2015) 0.75
To the Editor. Re: Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial. Menopause (2010) 0.75
The value of repeat BMD testing in elderly people. Climacteric (2014) 0.75
Menopausal hormone therapy and risk of hypertension. Climacteric (2012) 0.75
Cognitive behavior therapy and hot flushes. Climacteric (2014) 0.75
Treatment of hypercholesterolemia - a revolution. Climacteric (2014) 0.75
Recurrent venous thromboembolism in estrogen users. Climacteric (2014) 0.75
What if? Climacteric (2014) 0.75
Fibromyalgia and menopause: any link? Climacteric (2014) 0.75
Vitamins and bone health in women. Climacteric (2013) 0.75
Looking ahead: the WHIMS-Young study. Climacteric (2013) 0.75
Low-dose aspirin in primary prevention revisited. Climacteric (2014) 0.75
Neither long-term treatment with raloxifene nor hormone replacement therapy modulate cardiac function in healthy postmenopausal women: two randomized, placebo-controlled, 2-year studies. Am J Obstet Gynecol (2002) 0.75
Climacteric medicine: European Menopause and Andropause Society (EMAS) statements on postmenopausal hormonal therapy. Maturitas (2004) 0.75
Climacteric Commentaries. Climacteric (2012) 0.75
The heart of the WHI study: time for hormone therapy policies to be revised. Climacteric (2007) 0.75
WHI and breast cancer: a response to a recent publication from the WHI. Climacteric (2006) 0.75
Press statement. Breast cancer and hormone therapy: a looking-glass mirror? Climacteric (2007) 0.75
Climacteric commentaries. Climacteric (2014) 0.75
DXA vs. QUS to predict fracture risk. Climacteric (2013) 0.75
Lessons from RUTH. Climacteric (2006) 0.75
IMS reaction to recent breast cancer data. Climacteric (2007) 0.75
Critical comments. Maturitas (2003) 0.75
Why is the RUTH trial so important? Maturitas (2006) 0.75
Menopausal hormone therapy for primary prevention: why the USPSTF is wrong. Menopause (2017) 0.75
Breaking news: HRT to prevent chronic conditions. Climacteric (2013) 0.75
'Ma Nishtana'. Climacteric (2005) 0.75
Practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric (2004) 0.75
[What is the actual lesson from the WHI study upon its completion?]. Harefuah (2004) 0.75